Vertex Pharmaceuticals Incorporated (VRTX): Price and Financial Metrics

Vertex Pharmaceuticals Incorporated (VRTX)

Today's Latest Price: $241.31 USD

3.72 (1.57%)

Updated Jan 25 4:00pm

Add VRTX to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 484 in Biotech

See all "A" rated Strong Buy stocks

VRTX Stock Summary

  • VRTX has a market capitalization of $61,782,403,235 -- more than approximately 96.18% of US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, Vertex Pharmaceuticals Inc is reporting a growth rate of 258.97%; that's higher than 94.44% of US stocks.
  • Revenue growth over the past 12 months for Vertex Pharmaceuticals Inc comes in at 65.52%, a number that bests 91.97% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to Vertex Pharmaceuticals Inc, a group of peers worth examining would be REGN, TEAM, EA, MRNA, and LRCX.
  • VRTX's SEC filings can be seen here. And to visit Vertex Pharmaceuticals Inc's official web site, go to

VRTX Stock Price Chart Interactive Chart >

Price chart for VRTX

VRTX Price/Volume Stats

Current price $241.31 52-week high $306.08
Prev. close $237.59 52-week low $197.47
Day low $239.04 Volume 1,821,606
Day high $242.99 Avg. volume 1,795,742
50-day MA $228.42 Dividend yield N/A
200-day MA $257.23 Market Cap 62.75B

Vertex Pharmaceuticals Incorporated (VRTX) Company Bio

Vertex Pharmaceuticals engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases in specialty markets. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF); and advancing its research and early-stage development programs. The company was founded in 1989 and is based in Boston, Massachusetts.

VRTX Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$241.31$38590.66 16143%

We started the process of determining a valid price forecast for Vertex Pharmaceuticals Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Vertex Pharmaceuticals Inc ranked in the 98th percentile in terms of potential gain offered. As the table below shows, the model suggests the stock is dramatically undervalued -- investors should note, though, that such returns are always unlikely and not to be expected. In terms of the factors that were most noteworthy in this DCF analysis for VRTX, they are:

  • The company's debt burden, as measured by earnings divided by interest payments, is 52.77; that's higher than 92.93% of US stocks in the Healthcare sector that have positive free cash flow.
  • The business' balance sheet reveals debt to be 1% of the company's capital (with equity being the remaining amount). Approximately just 6.16% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
  • VRTX's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than 52.54% of tickers in our DCF set.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as VRTX, try THC, NVAX, BMRN, KMDA, and AMEH.

VRTX Latest News Stream

Event/Time News Detail
Loading, please wait...

VRTX Latest Social Stream

Loading social stream, please wait...

View Full VRTX Social Stream

Latest VRTX News From Around the Web

Below are the latest news stories about Vertex Pharmaceuticals Inc that investors may wish to consider to help them evaluate VRTX as an investment opportunity.

Vertex Pharmaceuticals: A Play On Market Overreaction

Investment Thesis Vertex Pharmaceuticals (VRTX) is a biopharmaceutical company that currently produces Cystic Fibrosis treatments. The disease is a genetic disorder that mostly affects the lungs, causing patients to experience difficulty breathing and frequent infections as a result of mucus buildup. They have also ventured into developing treatments for other...

BK Tan on Seeking Alpha | January 24, 2021

Vertex to Announce Fourth-Quarter 2020 Financial Results on February 1

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth-quarter 2020 financial results on Monday, February 1, 2021 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (866) 501-1537 (U.S.) or +1 (720) 545-0001 (International). The conference call will be webcast live and a link to the webcast can be accessed through Vertex's website at in the "Investors" se

Business Wire | January 22, 2021

Why the Earnings Surprise Streak Could Continue for Vertex (VRTX)

Vertex (VRTX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Yahoo | January 21, 2021

The Zacks Analyst Blog Highlights: CRISPR Therapeutics, Vertex Pharmaceuticals and Intellia Therapeutics

The Zacks Analyst Blog Highlights: CRISPR Therapeutics, Vertex Pharmaceuticals and Intellia Therapeutics

Yahoo | January 20, 2021

CRISPR (CRSP) Up More Than 80% in Past 3 Months: Here's Why

CRISPR Therapeutics' (CRSP) lead gene-editing candidate CTX001, being developed for treating SCD and TDT, holds potential. It has a strong partner in Vertex.

Yahoo | January 19, 2021

Read More 'VRTX' Stories Here

VRTX Price Returns

1-mo N/A
3-mo 13.72%
6-mo -13.42%
1-year 5.35%
3-year 42.61%
5-year 160.88%
YTD 2.10%
2020 7.94%
2019 32.13%
2018 10.58%
2017 103.42%
2016 -41.45%

Continue Researching VRTX

Want to see what other sources are saying about Vertex Pharmaceuticals Inc's financials and stock price? Try the links below:

Vertex Pharmaceuticals Inc (VRTX) Stock Price | Nasdaq
Vertex Pharmaceuticals Inc (VRTX) Stock Quote, History and News - Yahoo Finance
Vertex Pharmaceuticals Inc (VRTX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8082 seconds.